Rockwell Medical (NASDAQ:RMTI) Stock

ROCKWELL MEDICAL INC

Rockwell Medical

Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.

Rockwell Medical Inc

WIIM

RMTI

RMTI stock has given up its prior gain. Rockwell Medical shares were trading higher after the company reported better-than-expected Q1 financial results.

Rockwell Medical shares are trading higher after the company reported better-than-expected Q1 financial results.

GUIDANCE
Rockwell confirms its 2025 annual guidance as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2025 Annual Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Sales</td>
<td colspan="1" rowspan="1">$65.0M to $70.0M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Margin</td>
<td colspan="1" rowspan="1">16% to 18%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">($0.5)M to $0.5M</td>
</tr>
</tbody>
</table>
</figure>

News

Guidance

Rockwell Medical Affirms FY2025 Sales Guidance of $65.00M-$70.00M vs $67.42M Est

Earnings

Rockwell Medical Q1 2025 Adj. EPS $(0.01) Beats $(0.04) Estimate, Sales $18.91M Beat $16.77M Estimate

ACHC

ACHR

ACNT

AGEN

AIRJ

ALLT

ALTI

AMBC

AMPY

APEI

AQST

ARCT

ARWR

ASRT

ASYS

AUPH

BATRA

BATRK

Mobile Infrastructure Corporation Common Stock

BEEP

BETR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLDE

BLNK

CATX

CEPU

CHGG

CHRS

CLLS

CLPR

CMCL

CMPO

CNNE

CNTY

CPSS

CTMX

CTRI

CWCO

DOLE

EDIT

EXOD

FGEN

FOXA

FRPH

FTEK

FTRE

GAIA

GETY

GPRO

GRDN

HBIO

HFFG

HNRG

IHRT

IMNN

INDI

ISPR

KBDC

KPTI

KSPI

LAND

LEGH

LINC

LSEA

LTBR

METC

Ramaco Resources, Inc. - Class B Common Stock

METCB

MFIC

MLNK

MLYS

MNDY

MODG

MRVI

MVIS

MVST

NMRA

NOTE

NPWR

NRGV

NRXS

Earnings Scheduled For May 12, 2025

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares increased by 65.8% to $0.42 during Friday's pre-market session. The company's market cap stands at $16.7 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) shares increased by 16.81% to $2.64. The market value of their outstanding shares is at $154.6 million. The company's, Q1 earnings came out today. </li>
<li>American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) shares rose 16.15% to $7.19. The market value of their outstanding shares is at $113.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) stock moved upwards by 15.94% to $1.6. The company's market cap stands at $22.9 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares rose 12.93% to $1.22. The market value of their outstanding shares is at $41.5 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares moved upwards by 12.76% to $2.12. The market value of their outstanding shares is at $42.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) stock fell 18.8% to $0.82 during Friday's pre-market session. The company's market cap stands at $51.3 million. </li>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) stock decreased by 18.65% to $4.45. The company's market cap stands at $1.0 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares decreased by 17.45% to $0.22. The company's market cap stands at $10.0 million. </li>
<li>Tvardi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVRD#NASDAQ">TVRD</a>) shares fell 17.1% to $21.1. The company's market cap stands at $197.4 million. </li>
<li>Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) stock fell 15.76% to $9.25. The market value of their outstanding shares is at $3.8 billion. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares declined by 11.97% to $2.06. The market value of their outstanding shares is at $103.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AIRS

AMRN

AMWL

ARDX

ATPC

CAMP

CTSO

HCTI

MODV

PLRZ

TVRD

12 Health Care Stocks Moving In Friday's Pre-Market Session

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy and lowers the price target from $7 to $3.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Rockwell Medical, Lowers Price Target to $3

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock increased by 226.4% to $1.73 during Thursday's regular session. The market value of their outstanding shares is at $19.9 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares moved upwards by 205.28% to $1.56. The market value of their outstanding shares is at $9.1 million. </li>
<li>OptiNose (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) stock moved upwards by 54.63% to $9.28. The company's market cap stands at $93.2 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock rose 31.36% to $2.22. The company's market cap stands at $1.6 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock moved upwards by 27.84% to $11.98. The company's market cap stands at $98.8 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>ARS Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRY#NASDAQ">SPRY</a>) stock moved upwards by 26.43% to $14.73. The company's market cap stands at $1.4 billion. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) stock fell 38.8% to $0.29 during Thursday's regular session. The company's market cap stands at $17.3 million. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock decreased by 28.51% to $0.32. The market value of their outstanding shares is at $82.1 million. As per the press release, Q4 earnings came out today. </li>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares declined by 28.35% to $2.04. The company's market cap stands at $480.7 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock fell 20.28% to $2.59. The company's market cap stands at $1.7 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares fell 18.76% to $1.43. The market value of their outstanding shares is at $46.2 million. As per the news, the Q4 earnings report came out today. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares decreased by 17.1% to $1.94. The market value of their outstanding shares is at $1.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADAP

AKBA

BDRX

CRVO

ELEV

OPTN

PSTV

SPRY

VERO

WINT

12 Health Care Stocks Moving In Thursday's Intraday Session

Rockwell Medical shares are trading lower. The company reported Q4 financial results.

<h3>Gainers</h3>
<ul>
<li>OptiNose (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) shares moved upwards by 58.3% to $9.5 during Thursday's pre-market session. The market value of their outstanding shares is at $95.5 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock increased by 35.5% to $2.29. The company's market cap stands at $1.7 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock rose 20.99% to $0.62. The company's market cap stands at $3.6 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) shares moved upwards by 15.56% to $1.63. The company's market cap stands at $3.4 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares rose 13.01% to $0.85. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) stock rose 12.96% to $11.33. The market value of their outstanding shares is at $11.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) stock decreased by 23.9% to $2.16 during Thursday's pre-market session. The market value of their outstanding shares is at $510.2 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares declined by 16.67% to $1.95. The market value of their outstanding shares is at $1.3 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) shares fell 12.32% to $0.29. The company's market cap stands at $7.3 million. </li>
<li>GH Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) shares decreased by 12.32% to $10.4. The market value of their outstanding shares is at $645.0 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares declined by 9.1% to $1.6. The company's market cap stands at $51.7 million. The company's, Q4 earnings came out today. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock decreased by 9.07% to $0.35. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADTX

AEON

GHRS

MHUA

MSPR

TNFA

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.02 by 100 percent. This is a 100 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $24.70 million which beat the analyst consensus estimate of $23.65 million by 4.43 percent. This is a 11.80 percent increase over sales of $22.09 million the same period last year.

Earnings Beats

Rockwell Medical Q4 2024 Adj EPS $0.04 Beats $0.02 Estimate, Sales $24.70M Beat $23.65M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Star Equity Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRR#NASDAQ">STRR</a>) is projected to report quarterly loss at $0.17 per share on revenue of $14.00 million. 
• Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) is expected to report quarterly earnings at $1.82 per share on revenue of $1.68 billion. 
• Jabil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) is estimated to report quarterly earnings at $1.83 per share on revenue of $6.40 billion. 
• Mogo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOGO#NASDAQ">MOGO</a>) is likely to report quarterly loss at $0.08 per share on revenue of $12.77 million. 
• Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) is expected to report earnings for its fourth quarter. 
• Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $7.48 million. 
• InflaRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) is estimated to report quarterly loss at $0.28 per share on revenue of $125 thousand. 
• Beasley Broadcast Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBGI#NASDAQ">BBGI</a>) is likely to report earnings for its fourth quarter. 
• Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $8.42 million. 
• Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) is projected to report quarterly loss at $0.37 per share on revenue of $12.79 million. 
• Bragg Gaming Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRAG#NASDAQ">BRAG</a>) is estimated to report earnings for its fourth quarter. 
• Autolus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUTL#NASDAQ">AUTL</a>) is likely to report quarterly loss at $0.24 per share on revenue of $2.98 million. 
• Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) is estimated to report quarterly earnings at $2.79 per share on revenue of $3.22 billion. 
• FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) is likely to report quarterly earnings at $4.18 per share on revenue of $570.67 million. 
• Gambling.com Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>) is likely to report quarterly earnings at $0.24 per share on revenue of $35.14 million. 
• Destination XL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) is likely to report quarterly earnings at $0.03 per share on revenue of $120.93 million. 
• Titan Machinery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TITN#NASDAQ">TITN</a>) is estimated to report quarterly loss at $0.63 per share on revenue of $728.55 million. 
• Designer Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBI#NYSE">DBI</a>) is estimated to report quarterly loss at $0.49 per share on revenue of $719.32 million. 
• Caleres (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAL#NYSE">CAL</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $646.05 million. 
• NeueHealth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEUE#NYSE">NEUE</a>) is likely to report quarterly loss at $3.99 per share on revenue of $261.80 million. 
• Commercial Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) is estimated to report quarterly earnings at $0.30 per share on revenue of $1.75 billion. 
• Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) is expected to report quarterly earnings at $2.81 per share on revenue of $16.61 billion. 
• ARS Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRY#NASDAQ">SPRY</a>) is expected to report quarterly loss at $0.12 per share on revenue of $15.90 million. 
• ZEEKR Intelligent Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>) is projected to report earnings for its fourth quarter. 
• Shoe Carnival (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCVL#NASDAQ">SCVL</a>) is estimated to report quarterly earnings at $0.44 per share on revenue of $275.92 million. 
• 111 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YI#NASDAQ">YI</a>) is expected to report earnings for its fourth quarter. 
• Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $22.61 million. 
• VEON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) is expected to report quarterly earnings at $0.77 per share on revenue of $997.00 million. 
• Valneva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>) is estimated to report quarterly loss at $0.22 per share on revenue of $56.43 million. 
• H World Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) is projected to report quarterly earnings at $0.27 per share on revenue of $798.17 million. 
• 22nd Century Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) is estimated to report earnings for its fourth quarter. 
• Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) is projected to report earnings for its fourth quarter. 
• PDD Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) is likely to report quarterly earnings at $2.56 per share on revenue of $15.68 billion. 
• Yiren Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YRD#NYSE">YRD</a>) is likely to report earnings for its fourth quarter. 
• Neuraxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NRXS#AMEX">NRXS</a>) is likely to report earnings for its fourth quarter. 
• SPDR Select Sector Fund - Consumer Discretionary (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) is projected to report earnings for its fourth quarter. 
• Baozun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZUN#NASDAQ">BZUN</a>) is expected to report earnings for its fourth quarter. 
• Lands' End (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>) is expected to report quarterly earnings at $0.57 per share on revenue of $458.69 million. 
<h3>Companies Reporting After The Bell</h3>
• Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) is likely to report quarterly earnings at $0.29 per share on revenue of $11.01 billion. 
• FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) is likely to report quarterly earnings at $4.54 per share on revenue of $21.89 billion. 
• Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) is expected to report quarterly earnings at $1.42 per share on revenue of $7.89 billion. 
• United States Antimony (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAMY#AMEX">UAMY</a>) is estimated to report earnings for its fourth quarter. 
• SANUWAVE Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNWV#NASDAQ">SNWV</a>) is projected to report earnings for its fourth quarter. 
• Motorsport Games (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) is projected to report quarterly loss at $0.48 per share on revenue of $3.30 million. 
• Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) is projected to report earnings for its fourth quarter. 
• Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) is expected to report quarterly loss at $0.05 per share on revenue of $200 thousand. 
• Intellicheck (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDN#NASDAQ">IDN</a>) is likely to report quarterly loss at $0.01 per share on revenue of $5.07 million. 
• Vaxart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) is likely to report quarterly loss at $0.11 per share on revenue of $15.68 million. 
• Flux Power Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLUX#NASDAQ">FLUX</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $14.50 million. 
• Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) is likely to report quarterly loss at $0.85 per share on revenue of $1.75 million. 
• Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) is expected to report quarterly loss at $3.77 per share on revenue of $901 thousand. 
• Amprius Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $7.14 million. 
• Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) is projected to report quarterly loss at $0.07 per share on revenue of $263.00 million. 
• Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) is expected to report quarterly earnings at $1.73 per share on revenue of $7.44 billion. 
• Scholastic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCHL#NASDAQ">SCHL</a>) is projected to report quarterly loss at $0.78 per share on revenue of $347.68 million. 
• Arcadia Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKDA#NASDAQ">RKDA</a>) is projected to report quarterly loss at $0.50 per share on revenue of $1.15 million. 
• Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) is estimated to report quarterly loss at $0.66 per share on revenue of $30.93 million. 
• TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) is likely to report quarterly loss at $0.22 per share on revenue of $23.26 million. 
• Ouster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NASDAQ">OUST</a>) is likely to report quarterly loss at $0.26 per share on revenue of $30.00 million. 
• Luminar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) is projected to report quarterly loss at $0.15 per share on revenue of $17.43 million. 
• Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) is expected to report quarterly loss at $0.02 per share on revenue of $62.20 million. 
• KinderCare Learning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLC#NYSE">KLC</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $645.37 million. 
• Runway Gwth Fin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RWAY#NASDAQ">RWAY</a>) is likely to report quarterly earnings at $0.41 per share on revenue of $36.19 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALAR

AMPX

AUTL

BBGI

BRAG

BZUN

CBUS

CGTX

CURV

DXLG

FLUX

GAMB

GLUE

HTHT

IFRX

LAZR

MGNX

MOGO

MSGM

NEUE

OUST

Citigourp Global Markets 2% Protected Notes Linked To The Djia

QUBT

RKDA

RWAY

SCHL

SCVL

SKYE

SNWV

STRR

TELA

TITN

TNON

UAMY

VALN

VEEE

VEON

VXRT

Select Sector SPDR-Consumer Discretionary

XXII

Earnings Scheduled For March 20, 2025

General

Rockwell Medical Includes Single-Use Bicarbonate Cartridge To Hemodialysis Concentrates Product Portfolio

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy and maintains $7 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Rockwell Medical, Maintains $7 Price Target

Rockwell Medical shares are trading higher after the company announced expectations for $10 million in FY25 net sales and entered a purchase agreement with a provider of dialysis products and services.

Rockwell Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares are trading higher premarket on Tuesday after it entered into a product purchase agreement with a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42525272/rockwell-medical-enters-into-a-multi-year-product-purchase-agreement-with-the-worlds-leading-provi" rel="noreferrer noopener">provider of dialysis products and services</a>.
As per the three-year agreement, Rockwell Medical will supply its SteriLyte liquid bicarbonate product to the customer, with an option to renew it for two additional one-year terms.
The agreement is expected to generate over $10 million in net sales in the first year, a portion of which was not included in Rockwell Medical&#8217;s previously announced revenue estimates for 2025, with incremental price increases in subsequent years.
Last week, the company announced the promotion of Jesse Neri to the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42456143/rockwell-medical-promotes-jesse-neri-to-chief-financial-officer" rel="noreferrer noopener">post of Chief Financial Officer</a>.
This month, Rockwell Medical disclosed a partnership with HydroCare in which HydroCare will purchase and install Rockwell&#8217;s DAMX45 dry acid concentrate <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42334338/rockwell-medical-partners-with-hydrocare-to-distribute-and-install-its-dry-acid-concentrate-mix-sy" rel="noreferrer noopener">mix system in dialysis water rooms</a>.
This installation is expected to drive new sales for Rockwell&#8217;s dry acid hemodialysis concentrates.
Also, last month, the company inked a distribution deal with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42057509/rockwell-medical-expands-distribution-in-the-philippines" rel="noreferrer noopener">Nephro Group Dialysis Centers</a>.
Price Action: RMTI shares are up 14.4% at $2.29 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42526136" target="_blank" rel="noreferrer noopener">Asia Mostly Lower, Europe Markets Up As Dollar Strengthens Ahead Of Fed Rate Decision &#8211; Global Markets Today While US Slept</a></li>
</ul>
Image via Shutterstock.

Equities

Contracts

Small Cap

Rockwell Medical Scores Multi-Year Dialysis Deal; Stock Jumps

Under the terms of the Agreement, Rockwell Medical will supply the Customer with the Company's liquid bicarbonate hemodialysis concentrates product, SteriLyte.&nbsp;
The Agreement will remain in effect for three years with the option to renew for two additional one-year periods and is expected to generate upwards of $10 million in net sales for the Company in the first year, a portion of which was not included in Rockwell Medical's previously disclosed revenue estimates for 2025, with incremental price increases each subsequent year.

Rockwell Medical Enters Product Purchase Agreement With AProvider Of Dialysis Products And Services; Partnership Expected To Generate Upwards Of $10M In Net Sales For Company In 2025

Management

Rockwell Medical Promotes Jesse Neri To CFO

Rockwell anticipates that with these new mixer installations through HydroCare, the Company will also generate new sales related to its dry acid hemodialysis concentrates. Rockwell Medical's DAMX45 dry acid concentrate mix system is 510(k) approved to be used exclusively with the Company's CitraPure and Dri-Sate dry acid concentrate powders.&nbsp;

Health Care

Rockwell Medical Has Partnered With Hydrocare To Purchase And Install The Company's Dry Acid Concentrate Mix System In Dialysis Water Rooms

Comments

Rockwell Medical

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL